Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia.

OBJECTIVES The time to positivity (TTP) of blood cultures is associated with the microbial load in the blood and prognosis in patients with bloodstream infections caused by various bacterial species. However, relevant information about the TTP for Candida species in candidaemia is limited. We investigated the clinical impact of the TTP on mortality in patients with candidaemia. METHODS All consecutive patients ≥ 18 years of age with candidaemia between January 2006 and July 2012 were included. The demographics, clinical and microbiological characteristics, antifungal treatment and outcomes of the patients were collected retrospectively. RESULTS A total of 152 patients were identified. The overall mortality rate at 6 weeks was 53%. The median TTP for Candida isolates was 27 h (IQR 19-37 h). A TTP of ≤ 24 h was significantly related to a higher mortality rate (P = 0.021). In a multivariate Cox regression analysis, the Charlson comorbidity index value [adjusted hazard ratio (HR) 1.15, 95% CI 1.02-1.29, P = 0.018], sequential organ failure assessment score (adjusted HR 1.23, 95% CI 1.13-1.34, P < 0.001), TTP ≤ 24 h (adjusted HR 2.74, 95% CI 1.51-4.97, P = 0.001), timing of appropriate antifungal therapy >72 h (adjusted HR 2.38, 95% CI 1.26-4.51, P = 0.008) and persistent candidaemia (adjusted HR 2.50, 95% CI 1.33-4.72, P = 0.005) were independently associated with the 6 week mortality rate. CONCLUSIONS A short TTP (≤ 24 h) for Candida species was independently associated with increased mortality in patients with candidaemia. Additional studies on the relevance of the TTP to clinical outcome in patients with candidaemia are needed.

[1]  H. Choi,et al.  Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea , 2012, Annals of laboratory medicine.

[2]  P. Martín-Dávila,et al.  Emerging trends in candidemia: a higher incidence but a similar outcome. , 2012, The Journal of infection.

[3]  M. Kim,et al.  Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  P. Hsueh,et al.  Time to positivity of blood cultures of different Candida species causing fungaemia. , 2012, Journal of medical microbiology.

[5]  J. Layden,et al.  Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. , 2012, The Journal of antimicrobial chemotherapy.

[6]  E. García-Cabrera,et al.  Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  K. Laupland,et al.  Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. , 2010, The Journal of infection.

[8]  C. Liao,et al.  Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective cohort study. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  S. Seo,et al.  Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with Candidemia , 2009, Antimicrobial Agents and Chemotherapy.

[10]  G. Patel,et al.  The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock , 2009, American journal of therapeutics.

[11]  E. Anaissie,et al.  Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Rhee,et al.  SCORING SYSTEMS FOR PREDICTION OF MORTALITY IN PATIENTS WITH INTENSIVE CARE UNIT-ACQUIRED SEPSIS: A COMPARISON OF THE PITT BACTEREMIA SCORE AND THE ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION II SCORING SYSTEMS , 2009, Shock.

[14]  R. Ben-Ami,et al.  Time to Blood Culture Positivity as a Marker for Catheter-Related Candidemia , 2008, Journal of Clinical Microbiology.

[15]  M. Pfaller,et al.  Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. , 2008, Diagnostic microbiology and infectious disease.

[16]  I. de Benito,et al.  Time-to-positivity in patients with Escherichia coli bacteraemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[18]  S. Fridkin,et al.  Impact of early central venous catheter removal on outcome in patients with candidaemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Peralta,et al.  Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia , 2006, BMC infectious diseases.

[21]  B. A. Forbes,et al.  Time to Blood Culture Positivity as a Predictor of Clinical Outcome of Staphylococcus aureus Bloodstream Infection , 2006, Journal of Clinical Microbiology.

[22]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[23]  D. Hospenthal,et al.  Effect of Inoculum Size on Detection of Candida Growth by the BACTEC 9240 Automated Blood Culture System Using Aerobic and Anaerobic Media , 2005, Journal of Clinical Microbiology.

[24]  L. Rubin,et al.  Initial Concentration of Staphylococcus epidermidis in Simulated Pediatric Blood Cultures Correlates with Time to Positive Results with the Automated, Continuously Monitored BACTEC Blood Culture System , 2002, Journal of Clinical Microbiology.

[25]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[26]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[27]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[28]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[29]  P. Della‐Latta,et al.  The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. , 2010, Medical mycology.

[30]  Li Guanghu,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America , 2010 .

[31]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[32]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.